CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state

Antony, Marie Lue; Chang, Daniel T.; Noble-Orcutt, Klara E.; Kay, A. B.; Jensen, Jeffrey L.; Mohei, Hesham; Myers, Chad L.; Sachs, Karen; Sachs, Zohar

doi:10.1080/10428194.2023.2207698

Cited by 1 publication

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CD69 expressed in cancer cells facilitated the progression of carcinoma cell through its interaction with fibronectin, consequently contributing to an adverse prognosis for patients. 69 Another study found a subset of leukemia stem cells with high CD69 expression levels corresponding to self-renewal and enhanced colony-forming capacity, which is responsible for the relapse of acute myeloid leukemia 70 , 71 and poor and poor clinical outcomes. 70 Moreover, CD69 expression was also detected on tumor cells from most other hematological malignancies and was associated with poor clinical outcome.…”

Section: Introductionmentioning

confidence: 99%

CD69 is a Promising Immunotherapy and Prognosis Prediction Target in Cancer

Li,

Gu,

Yang

et al. 2024

ITT

View full text Add to dashboard Cite

Immunotherapy utilizing T cells that attack tumors is a promising strategy for treatment, but immune suppressive T cell subsets, such as regulatory T cell (Treg), and immune checkpoint molecules, including programmed death-1 (PD-1), can suppress the intensity of a T cell immune reaction and thereby impair tumor clearance. Cluster of differentiation 69 (CD69), known as an early leukocyte activation marker, can be used as a measure or early marker of T cell activation. In recent years, the functions of CD69 in the regulation of Treg/Th17 (T helper cell 17) differentiation and in the tissue retention of T cells have attracted considerable interest. These functions are related to the role of CD69 in immune suppression in tumor environments (TME). In this review, we first summarized current perspectives in the biological function of CD69 and demonstrated that CD69 acts as a regulator of T cell activation, differentiation, retention, and exhaustion. Then, we discussed recent advances in understanding of CD69 deficiency and anti-CD69 antibody administration and shed light on the value of targeting on CD69 for cancer immunotherapy and prognosis prediction.

show abstract